达格列净与复方α-酮酸联合治疗慢性肾脏病的临床效果及其机制研究  

Clinical effect and mechanism of daglizin and compound alpha-ketoacid in the treatment of chronic kidney disease

作　　者：陈俊杰 周雪艳 皮红艳 谢明娇 Chen Junjie;Zhou Xueyan;Pi Hongyan;Xie Mingjiao(Second People's Hospital of Kunming,Kunming,Yunnan 650031,China)

机构地区：[1]昆明市第二人民医院,云南昆明650031

出　　处：《首都食品与医药》2025年第3期71-74,共4页Capital Food Medicine

摘　　要：目的探讨达格列净联合复方α-酮酸治疗慢性肾脏病(Chronic Kidney Disease,CKD)患者的临床效果及其机制.方法选取2023年1月-2023年12月74例CKD患者,按随机数表法均分为对照组与实验组.对照组(n=37)给予复方α-酮酸治疗,实验组(n=37)给予达格列净联合复方α-酮酸治疗,比较两组治疗前后肾功能指标[血肌酐(Cr)、肾小球滤过率(eGFR)、尿素氮(BUN)、24小时尿蛋白定量(Uprot)、白蛋白(Alb)]、肾脏微循环[血清内皮素-1(ET-1)、血管性血友病因子(vWF)]、肾脏炎症指标[白介素-6(IL-6)、肿瘤坏死因子-α(TNF-α)、超敏C反应蛋白(hs-CRP)]、肾间质纤维化标志物[同型半胱氨酸(Hcy)、血管内皮生长因子(VEGF)、肝细胞生长因子(HGF)]及不良反应.结果治疗3个月后,实验组血Cr、BUN、Uprot水平低于对照组,eGFR、Alb水平高于对照组(P均<0.05);实验组血清ET-1、vWF水平均低于对照组(P均<0.05);实验组血清IL-6、TNF-α、hs-CRP水平均低于对照组(P均<0.05);实验组血清Hcy、VEGF水平低于对照组,HGF水平高于对照组(P均<0.05);两组不良反应发生率比较,差异不显著(P>0.05).结论达格列净联合复方α-酮酸能够改善慢性肾脏病患者的肾功能与炎症指标,降低血肌酐及尿蛋白水平,且无明显不良反应,支持其在CKD治疗中的临床应用.Objective To investigate the clinical effect and mechanism of dagaglizin combined with compound alpha-ketoacid in the treatment of Chronic Kidney Disease(CKD).Methods 74 patients with CKD from January 2023 to December 2023 were selected and divided into control group and experimental group according to random number table method.The control group(n=37)was treated with compound alpha-keto acid,and the experimental group(n=37)was treated with dagaglizin combined with compound alpha-keto acid.Compare renal function indexes[serum creatinine(Cr),glomerular filtration rate(eGFR),urea nitrogen(BUN),24-hour urinary protein quantitative(Uprot),albumin(Alb)],renal microcirculation[serum endothelin-1(ET-1),von Willefibrilia factor(vWF)],renal inflammation[interleukin-6(IL-6),tumor necrosis factor(TNF-α),hypersensitive C-reactive protein(hs-CRP)],markers of renal interstitial fibrosis[homocysteine(Hcy),vascular endothelial growth factor(VEGF),hepatocyte growth factor(HGF)]and adverse reactions between two groups before and after treatment.Results After 3 months of treatment,the levels of blood Cr,BUN and Uprot in experimental group were lower than those in control group,eGFR and Alb were higher than those in control group(P<0.05),serum ET-1 and vWF levels in experimental group were lower than those in control group(P<0.05),the levels of IL-6,TNF-αand hs-CRP in the experimental group were lower than those in the control group(P<0.05),serum Hcy and VEGF levels in experimental group were lower than those in control group,and HGF levels were higher than those in control group(P<0.05).The incidence of adverse reactions was compared between the two groups(P>0.05).Conclusion Daaglipzin combined with compound alpha-ketoacid can improve renal function and inflammatory indexes,reduce serum creatinine and urinary protein in patients with chronic kidney disease without obvious adverse reactions,which supports its clinical application in the treatment of CKD.

关 键 词：达格列净 复方Α-酮酸 慢性肾脏病 肾功能 炎症指标 

分 类 号：R69[医药卫生—泌尿科学]